Mushroom Protocol utilizes decentralized finance and smart contracts to connect early-stage biotechnology companies with global investors, enabling fractional ownership of intellectual property and equity. This approach addresses the challenge of securing funding for biotech startups while allowing them to maintain control over their innovations.
Funding
Funding not disclosed
Founders
Product
Problem
Early-stage biotechnology companies often struggle to secure funding through traditional venture capital, limiting their ability to develop and commercialize innovative research. Investors, in turn, face challenges accessing and diversifying their portfolios with early-stage biotech opportunities due to high entry barriers and information asymmetry.
Solution
Mushroom Protocol connects early-stage biotechnology companies with a global network of investors through decentralized finance (DeFi) and smart contracts. The platform enables fractional ownership of intellectual property (IP) and equity in biotech startups, allowing investors to participate with smaller capital outlays. By tokenizing IP and equity, Mushroom Protocol creates a liquid market for biotech assets, increasing accessibility and transparency. The $FUNGI governance token allows community members to vote on projects and startups to receive investment. The platform facilitates the exchange of $FUNGI for IP-tokens or share-tokens from biotech companies and offers staking strategies to earn rewards.
Target Audience
The primary target audience includes early-stage biotechnology companies seeking alternative funding sources and individual or institutional investors interested in gaining exposure to the biotech sector with reduced capital requirements.
Features
- Fractional ownership of biotech IP and equity through tokenization
- Decentralized governance via the $FUNGI token for investment decisions
- DeFi-based platform for trading and staking biotech assets
- Smart contract-enabled automation of investment and distribution processes
- Portfolio diversification across multiple early-stage biotech ventures